|
Jun 29
|
Immutep (IMMP) Announces Positive Initial Efficacy Data and Continued Favourable Safety Data
|
|
Jun 26
|
ASX Penny Stocks Spotlight: Arafura Rare Earths And Two More To Consider
|
|
Jun 24
|
With 51% institutional ownership, Immutep Limited (ASX:IMM) is a favorite amongst the big guns
|
|
Jun 23
|
High Growth Tech Stocks In Australia For June 2025
|
|
Jun 23
|
Immutep Announces Positive Update from Phase I Study of IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases
|
|
Jun 19
|
Exploring Life360 And 2 Prominent High Growth Tech Stocks In Australia
|
|
May 27
|
Immutep’s Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma
|
|
May 15
|
Immutep’s Efti with KEYTRUDA® (pembrolizumab) & Chemotherapy Achieves High Response Rates in First-Line Non-Small Cell Lung Cancer
|
|
Mar 10
|
Immutep Limited (IMMP): Among the Best Australian Stocks to Buy According to Billionaires
|
|
Feb 11
|
Is Immutep Limited (IMMP) the Best Long Term ASX Stock to Buy Now?
|
|
Jan 6
|
Patient Enrolment Completed for INSIGHT-003
|
|
Oct 10
|
Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit
|
|
Jun 25
|
Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for Cancer
|
|
Mar 24
|
11 Best ASX Stocks To Buy Now
|
|
Feb 5
|
10 Best Australian Stocks To Buy
|
|
Jan 4
|
First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial Cancer
|
|
Dec 21
|
Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer
|
|
Dec 7
|
Immutep Receives A$2.6 million R&D Tax Incentive from French Government
|
|
Nov 27
|
Immutep (ASX:IMM) investors are sitting on a loss of 22% if they invested five years ago
|
|
Nov 9
|
Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA® in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma
|